160 related articles for article (PubMed ID: 26237184)
1. Genetic variants in 6-mercaptopurine pathway as potential factors of hematological toxicity in acute lymphoblastic leukemia patients.
Hareedy MS; El Desoky ES; Woillard JB; Thabet RH; Ali AM; Marquet P; Picard N
Pharmacogenomics; 2015; 16(10):1119-34. PubMed ID: 26237184
[TBL] [Abstract][Full Text] [Related]
2. Genetic polymorphism of inosine-triphosphate-pyrophosphatase influences mercaptopurine metabolism and toxicity during treatment of acute lymphoblastic leukemia individualized for thiopurine-S-methyl-transferase status.
Stocco G; Crews KR; Evans WE
Expert Opin Drug Saf; 2010 Jan; 9(1):23-37. PubMed ID: 20021291
[TBL] [Abstract][Full Text] [Related]
3. Effect of polymorphisms in transporter genes on dosing, efficacy and toxicity of maintenance therapy in children with acute lymphoblastic leukemia.
Gervasini G; de Murillo SG; Jiménez M; de la Maya MD; Vagace JM
Gene; 2017 Sep; 628():72-77. PubMed ID: 28710036
[TBL] [Abstract][Full Text] [Related]
4. Impact of single nucleotide polymorphisms of cytarabine metabolic genes on drug toxicity in childhood acute lymphoblastic leukemia.
Gabor KM; Schermann G; Lautner-Csorba O; Rarosi F; Erdelyi DJ; Endreffy E; Berek K; Bartyik K; Bereczki C; Szalai C; Semsei AF
Pediatr Blood Cancer; 2015 Apr; 62(4):622-8. PubMed ID: 25557962
[TBL] [Abstract][Full Text] [Related]
5. Polymorphism of ITPA 94C>A and risk of adverse effects among patients with acute lymphoblastic leukaemia treated with 6-mercaptopurine.
Wan Rosalina WR; Teh LK; Mohamad N; Nasir A; Yusoff R; Baba AA; Salleh MZ
J Clin Pharm Ther; 2012 Apr; 37(2):237-41. PubMed ID: 21545474
[TBL] [Abstract][Full Text] [Related]
6. The low frequency of defective TPMT alleles in Turkish population: a study on pediatric patients with acute lymphoblastic leukemia.
Tumer TB; Ulusoy G; Adali O; Sahin G; Gozdasoglu S; Arinç E
Am J Hematol; 2007 Oct; 82(10):906-10. PubMed ID: 17617792
[TBL] [Abstract][Full Text] [Related]
7. Pathway genes and metabolites in thiopurine therapy in Korean children with acute lymphoblastic leukaemia.
Choi R; Sohn I; Kim MJ; Woo HI; Lee JW; Ma Y; Yi ES; Koo HH; Lee SY
Br J Clin Pharmacol; 2019 Jul; 85(7):1585-1597. PubMed ID: 30927276
[TBL] [Abstract][Full Text] [Related]
8. APEX1 Polymorphism and Mercaptopurine-Related Early Onset Neutropenia in Pediatric Acute Lymphoblastic Leukemia.
Kim H; Seo H; Park Y; Min BJ; Seo ME; Park KD; Shin HY; Kim JH; Kang HJ
Cancer Res Treat; 2018 Jul; 50(3):823-834. PubMed ID: 28882023
[TBL] [Abstract][Full Text] [Related]
9. PACSIN2 polymorphism is associated with thiopurine-induced hematological toxicity in children with acute lymphoblastic leukaemia undergoing maintenance therapy.
Smid A; Karas-Kuzelicki N; Jazbec J; Mlinaric-Rascan I
Sci Rep; 2016 Jul; 6():30244. PubMed ID: 27452984
[TBL] [Abstract][Full Text] [Related]
10. Thiopurine pharmacogenomics: association of SNPs with clinical response and functional validation of candidate genes.
Matimba A; Li F; Livshits A; Cartwright CS; Scully S; Fridley BL; Jenkins G; Batzler A; Wang L; Weinshilboum R; Lennard L
Pharmacogenomics; 2014 Mar; 15(4):433-47. PubMed ID: 24624911
[TBL] [Abstract][Full Text] [Related]
11. Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia.
Stocco G; Cheok MH; Crews KR; Dervieux T; French D; Pei D; Yang W; Cheng C; Pui CH; Relling MV; Evans WE
Clin Pharmacol Ther; 2009 Feb; 85(2):164-72. PubMed ID: 18685564
[TBL] [Abstract][Full Text] [Related]
12. Frequency of ITPA gene polymorphisms in Iranian patients with acute lymphoblastic leukemia and prediction of its myelosuppressive effects.
Azimi F; Mortazavi Y; Alavi S; Khalili M; Ramazani A
Leuk Res; 2015 Oct; 39(10):1048-54. PubMed ID: 26242828
[TBL] [Abstract][Full Text] [Related]
13. [Susceptibility to 6-mercaptopurine toxicity related with NUDT15 and ABCC4 variants in Japanese childhood acute lymphoblastic leukemia].
Tanaka Y
Rinsho Ketsueki; 2017; 58(8):950-956. PubMed ID: 28883280
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetic evaluation of 6-mercaptopurine-mediated toxicity in pediatric acute lymphoblastic leukemia patients from a South Indian population.
Ramalingam R; Kaur H; Scott JX; Sneha LM; Arun Kumar GP; Srinivasan A; Paul SF
Pharmacogenomics; 2021 May; 22(7):401-411. PubMed ID: 33876659
[No Abstract] [Full Text] [Related]
15. Interaction between NUDT15 and ABCC4 variants enhances intolerability of 6-mercaptopurine in Japanese patients with childhood acute lymphoblastic leukemia.
Tanaka Y; Nakadate H; Kondoh K; Nakamura K; Koh K; Manabe A
Pharmacogenomics J; 2018 Apr; 18(2):275-280. PubMed ID: 28418010
[TBL] [Abstract][Full Text] [Related]
16. Influence of MTHFR and RFC1 polymorphisms on toxicities during maintenance chemotherapy for childhood acute lymphoblastic leukemia or lymphoma.
Shimasaki N; Mori T; Torii C; Sato R; Shimada H; Tanigawara Y; Kosaki K; Takahashi T
J Pediatr Hematol Oncol; 2008 May; 30(5):347-52. PubMed ID: 18458567
[TBL] [Abstract][Full Text] [Related]
17. Thiopurine S-methyltransferase (TPMT) polymorphisms in children with acute lymphoblastic leukemia, and the need for reduction or cessation of 6-mercaptopurine doses during maintenance therapy: the Polish multicenter analysis.
Peregud-Pogorzelski J; Tetera-Rudnicka E; Kurzawski M; Brodkiewicz A; Adrianowska N; Mlynarski W; Januszkiewicz D; Drozdzik M
Pediatr Blood Cancer; 2011 Oct; 57(4):578-82. PubMed ID: 21319286
[TBL] [Abstract][Full Text] [Related]
18. Analysis of thiopurine S-methyltransferase polymorphism in the population of Serbia and Montenegro and mercaptopurine therapy tolerance in childhood acute lymphoblastic leukemia.
Dokmanovic L; Urosevic J; Janic D; Jovanovic N; Petrucev B; Tosic N; Pavlovic S
Ther Drug Monit; 2006 Dec; 28(6):800-6. PubMed ID: 17164697
[TBL] [Abstract][Full Text] [Related]
19. Assessment of mercaptopurine (6MP) metabolites and 6MP metabolic key-enzymes in childhood acute lymphoblastic leukemia.
Wojtuszkiewicz A; Barcelos A; Dubbelman B; De Abreu R; Brouwer C; Bökkerink JP; de Haas V; de Groot-Kruseman H; Jansen G; Kaspers GL; Cloos J; Peters GJ
Nucleosides Nucleotides Nucleic Acids; 2014; 33(4-6):422-33. PubMed ID: 24940700
[TBL] [Abstract][Full Text] [Related]
20. Genetic variants of thiopurine and folate metabolic pathways determine 6-MP-mediated hematological toxicity in childhood ALL.
Dorababu P; Naushad SM; Linga VG; Gundeti S; Nagesh N; Kutala VK; Reddanna P; Digumarti R
Pharmacogenomics; 2012 Jul; 13(9):1001-8. PubMed ID: 22838948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
